Thus, our above analyses show that both SETD2 alternative variants and downregulation lead to gene body hypomethylation in almost all cancer types tested. This suggests that these SETD2-dependent DNA methylation changes are due to loss of H3K36me3 which occurs in the gene body. The gene discussed is SETD2; the disease is cancer.